Literature DB >> 4938243

Baclofen in the treatment of spasticity.

P Hudgson, D Weightman.   

Abstract

Baclofendagger (Lioresal), a derivative of gamma-aminobutyric acid, was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Preliminary studies suggested that it may be more effective than other spasmolytic agents currently available, and a double-blind controlled trial in a group of 23 patients against placebo has shown it to be significantly more effective.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4938243      PMCID: PMC1799146          DOI: 10.1136/bmj.4.5778.15

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  5 in total

1.  Intrathecal phenol to relieve spasticity in paraplegia.

Authors:  P W NATHAN
Journal:  Lancet       Date:  1959-12-19       Impact factor: 79.321

2.  Gaba derivative in spasticity. (Beta-(4-chlorophenyl)-gamma-aminobutyric acid, Ciba 34.647-Ba).

Authors:  E Pedersen; P Arlien-Soborg; V Grynderup; O Henriksen
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

3.  A new agent for the control of spasticity.

Authors:  R F Jones; D Burke; J E Marosszeky; J D Gillies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-08       Impact factor: 10.154

Review 4.  The pharmacology of amino acids related to gamma-aminobutyric acid.

Authors:  D R Curtis; J C Watkins
Journal:  Pharmacol Rev       Date:  1965-12       Impact factor: 25.468

5.  On the site of action of diazepam in spasticity in man.

Authors:  J B Cook; P W Nathan
Journal:  J Neurol Sci       Date:  1967 Jul-Aug       Impact factor: 3.181

  5 in total
  19 in total

1.  Effect of baclofen upon monosynaptic and tonic vibration reflexes in patients with spasticity.

Authors:  D L Mclellan; D L Maclellan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-08       Impact factor: 10.154

2.  Editorial: Control of spasticity.

Authors: 
Journal:  Br Med J       Date:  1973-12-29

3.  Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis.

Authors:  D W Hedley; J A Maroun; M L Espir
Journal:  Postgrad Med J       Date:  1975-09       Impact factor: 2.401

4.  Variations in GP night visiting rates: medical organisation and consumer demand.

Authors:  M J Buxton; R E Klein; J Sayers
Journal:  Br Med J       Date:  1977-03-26

Review 5.  Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1974       Impact factor: 9.546

6.  Pharmacology of M & B 18,706, a drug which selectively reduces decerebrate rigidity.

Authors:  D R Maxwell; M A Read; E A Sumpter
Journal:  Br J Pharmacol       Date:  1974-01       Impact factor: 8.739

7.  The use of intrathecal phenol for muscle spasms in multiple sclerosis. A description of two cases.

Authors:  R A Browne; D V Catton
Journal:  Can Anaesth Soc J       Date:  1975-03

8.  Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

Authors:  Uwe K Zettl; Thomas Henze; Ute Essner; Peter Flachenecker
Journal:  Eur J Health Econ       Date:  2013-12-01

9.  Influence of baclofen on laryngeal and spinal motor drive during cough in the anesthetized cat.

Authors:  Daniel Castillo; Teresa Pitts
Journal:  Laryngoscope       Date:  2013-05-13       Impact factor: 3.325

10.  Prospective Randomized Study of Oral Diazepam and Baclofen on Spasticity in Cerebral Palsy.

Authors:  Vinay Goyal; Nonica Laisram; Ranjan Kumar Wadhwa; Shashank Yashwant Kothari
Journal:  J Clin Diagn Res       Date:  2016-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.